Health coverage company Centene (NYSE: CNC) announced better-than-expected revenue in Q3 2026, with sales up 1.9% year on year to $50.65 billion. The company’s full-year revenue guidance of $198.5 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.58 per share was significantly above analysts’ consensus estimates.

Is now the time to buy CNC? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Centene delivered better-than-expected results in Q3 2026, buoyed by strength in its Medicare and Marketplace businesses. Management highlighted that favorable medical cost trends in Medicare Advantage and disciplined cost management in Medicaid helped offset utilization pressures in specific geographies, such as Florida. CEO Sarah London emphasized continued stabilization in behavioral health and home health trends, as well as effective fraud and abuse controls, as key drivers of the quarter. The company also noted strong execution in its turnaround plan for both Medicare and the Marketplace, with the latter absorbing adjustments from integrity measures without derailing profitability.

Looking ahead, Centene’s updated guidance is anchored by expectations for further margin expansion in its Medicare and Marketplace businesses and more effective rate alignment in Medicaid. Management signaled that ongoing cost optimization and operational streamlining, including automation and AI, should contribute to lower SG&A expenses in 2027. CFO Drew Asher stated that the company anticipates “continued progress matching Medicaid rates with acuity,” while London pointed to proactive state engagement on rate-setting and work requirements as critical for navigating membership shifts and maintaining margin recovery next year.

Key insights from management’s remarks

Management attributed the quarter’s outperformance to robust Medicare results, continued margin improvement in Marketplace, and disciplined cost controls across the portfolio.

• Medicare segment turnaround: The Medicare Advantage and standalone Part D (PDP) businesses both performed better than expected, with Medicare Advantage reaching financial breakeven a year ahead of schedule due to lower-than-anticipated medical costs and targeted portfolio adjustments.
• Marketplace margin expansion: The Marketplace segment saw continued margin improvement, driven by moderating trends in higher-acuity silver tier products and successful integration of cost integrity measures, including responses to unauthorized enrollment and independent dispute resolution claims.
• Medicaid stabilization and rate actions: Medicaid performance remained on track, supported by positive rate actions, effective member and provider engagement, and a diverse set of cost management initiatives, particularly in behavioral health and home health. Management noted that ongoing eligibility “cleanups” and work requirement preparations were absorbed without derailing overall performance.
• SG&A efficiency gains: Operational streamlining, process simplification, and increased use of automation and AI contributed to a lower SG&A expense ratio, with management expecting further durable improvements into 2027 as enterprise optimization efforts continue.
• Debt reduction and financial flexibility: The company reduced total debt to $15 billion, enhancing near-term financial flexibility and lowering interest expense, which management views as creating capacity for future growth initiatives.

Drivers of future performance

Centene’s outlook for next year is shaped by ongoing Medicaid eligibility changes, margin recovery in Medicare and Marketplace, and efforts to sustain SG&A improvements.

• Medicaid eligibility and rate alignment: Management expects incremental membership declines from work requirements and eligibility reviews to continue, but believes proactive engagement with states and data-driven rate-setting should help offset acuity shifts and support gradual margin improvement.
• Medicare and Marketplace margin trajectory: The company anticipates Medicare Advantage will move from breakeven to positive margins, while Marketplace is positioned for further margin expansion as pricing strategies and tier mix adjustments are refined for 2027. Management highlighted the importance of maintaining affordability while harvesting margin gains.
• Enterprise cost discipline: Continued investment in automation, simplification of operations, and workforce optimization are expected to provide durable SG&A reductions, supporting profitability even as topline growth moderates.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will monitor (1) Medicaid membership trends as states implement work requirements and conduct eligibility reviews, (2) the pace and sustainability of margin gains in both Medicare and Marketplace segments as product and pricing strategies evolve, and (3) ongoing SG&A optimization through automation and operational streamlining. The ability to maintain positive state relationships and adapt to regulatory changes will also be key signs of execution.

Centene currently trades at $67.75, in line with $68.03 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our favorite stocks right now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.